scholarly journals One size does not fit all: towards personalized risk assessment in travel medicine

2018 ◽  
Vol 25 (1) ◽  
Author(s):  
Gerard T Flaherty
Keyword(s):  
Risk Assessment ◽  
Travel Medicine ◽  
Personalized Risk Assessment ◽  
Personalized Risk

Ancestry‐specific hereditary cancer panel yields: Moving toward more personalized risk assessment

2020 ◽  
Vol 29 (4) ◽  
pp. 598-606
Author(s):  
Maegan E. Roberts ◽  
Lisa R. Susswein ◽  
Wanchun Janice Cheng ◽  
Natalie J. Carter ◽  
Amber C. Carter ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Hereditary Cancer ◽  
Personalized Risk Assessment ◽  
Personalized Risk ◽  
Cancer Panel

scholarly journals Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study

2018 ◽  
Vol 196 ◽  
pp. 36-48 ◽  
Author(s):  
Nick van Boven ◽  
Linda C. Battes ◽  
K. Martijn Akkerhuis ◽  
Dimitris Rizopoulos ◽  
Kadir Caliskan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Risk Assessment ◽  
Chronic Heart Failure ◽  
Troponin T ◽  
Temporal Patterns ◽  
Personalized Risk Assessment ◽  
Personalized Risk ◽  
Shift Study

Personalized Risk Assessment of Adverse Cardiovascular Events in Young Patients With Connective Tissue Dysplasia

Kardiologiia ◽  
2015 ◽  
Vol 3_2015 ◽  
pp. 75-84 ◽  
Author(s):  
I.V. Druk Druk ◽  
G.I. Nechaeva Nechaeva ◽  
O.V. Oseeva Oseeva ◽  
E.G. Pomorgajlo Pomorgajlo ◽  
V.N. Maksimov Maksimov ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Connective Tissue ◽  
Cardiovascular Events ◽  
Young Patients ◽  
Connective Tissue Dysplasia ◽  
Personalized Risk Assessment ◽  
Personalized Risk

scholarly journals Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Xifeng Wu ◽  
Chi Pang Wen ◽  
Yuanqing Ye ◽  
MinKwang Tsai ◽  
Christopher Wen ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Prospective Cohort ◽  
Personalized Risk Assessment ◽  
Personalized Risk ◽  
Heavy Smokers

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

scholarly journals Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Jure Knez ◽  
Monika Sobocan ◽  
Urska Belak ◽  
Rajko Kavalar ◽  
Mateja Zupin ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Endometrial Cancer ◽  
European Society ◽  
Molecular Classification ◽  
Intermediate Risk ◽  
Clinical Risk ◽  
Mutational Status ◽  
Clinical Risk Assessment ◽  
Personalized Risk Assessment ◽  
Personalized Risk

Abstract Background The aim of this study was to evaluate changes in prognostic risk profiles of women with endometrial cancer by comparing the clinical risk assessment with the integrated molecular risk assessment profiling. Patients and methods This prospective study recruited patients with biopsy proven endometrial cancer treated at the University Medical Centre Maribor between January 2020 to February 2021. Patient clinical data was assessed and categorized according to the currently valid European Society of Gynaecological Oncology, European SocieTy for Radiotherapy and Oncology, and European Society of Pathology (ESGO/ESTRO/ESP) guidelines on endometrial cancer. Molecular tumour characterization included determination of exonuclease domain of DNA polymerase-epsilon (POLE) mutational status by Sanger sequencing and imunohistochemical specimen evaluation on the presence of mismatch repair deficiencies (MMRd) and p53 abnormalities (p53abn). Results Fourty-five women were included in the study. Twenty-two tumours were of non-specific mutational profile (NSMP) (56.4%), 13 were classified as MMRd (33.3%), 3 were classified as p53abn (7.7%) and 1 was classified as POLE mutated (2.6%). Six tumours (15.4%) had multiple molecular classifiers, these were studied separately and were not included in the risk assessment. The clinical risk-assessment classified 21 women (53.8%) as low-risk, 5 women (12.8%) as intermediate risk, 2 women as high-intermediate risk (5.1%), 10 women (25.6%) as high risk and 1 patient as advanced metastatic (2.6%). The integrated molecular classification changed risk for 4 women (10.3%). Conclusions Integrated molecular risk improves personalized risk assessment in endometrial cancer and could potentially improve therapeutic precision. Further molecular stratification with biomarkers is especially needed in the NSMP group to improve personalized risk-assessment.

Sign in / Sign up

Export Citation Format

Share Document